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Fc-32-001
pisa syndrome induced by atypical antipsychotics
Susana Mendes
HNSR - Departamento Psquiatria, Lisboa, Portugal
Susana Fernandes, Guida Ponte
objectives: Pisa syndrome, or tonic flexion of the trunk, long considered 
a side effect of prolonged exposure to conventional antipsychotics, has 
been reported as occurring with atypical antipsychotics. The authors re-
port two cases of Pisa syndrome induced by atypical antipsychotics. 
methods: Literature review derived from the MEDLINE and PUBMED da-
tabase
results: Case One - 38 years old male with type I Bipolar Disorder, pre-
sented with insidious onset tonic truncal flexion with axial rotation and 
difficulty in walking after exposure to olanzapine in doses up to 20 mg/
day for 9 months. An objective causality assessment suggested that Pisa 
syndrome was probably related to olanzapine. There was improvement 
in his symptoms after 4 weeks switching olanzapine to zotepine in doses 
gradually titrated to 200 mg/day. Case two – 26 years old male with 
moderate mental retardation, treated with long-acting risperidone 25 
mg - 15/15 days for is aggressive and self-injurious behavior secondary 
to mood disorder, developed a acute onset of Pisa syndrome, when pre-
scribed with 50 mg 15/15 dosage. The symptoms disappeared returning 
to 25 mg of long acting risperidone. 
conclusions: Pisa syndrome is a type of dystonia that has been associat-
ed with both typical and atypical antipsychotics. Both acute and insidious 
onset cases have been described in the literature, which have different 
course and treatment response. Once the patient presents Pisa syndrome, 
the treatment may include the reduction in dosage or discontinuation of 
the antipsychotic drug, associated to the introduction of an anticholiner-
gic medication. In the follow-up drugs with low affinity for dopaminergic 
D2 receptors should be used.
Fc-32-002
randomized placebo controlled trials of n-acetyl cysteine as ad-
junct therapy for schizophrenia and bipolar disorder
Ashley Bush
Mental Health Research Inst., The University of Melbourne, Australia
Olivia Dean, D.L. Copolov, M. Berk
abstract: Glutathione is the principal antioxidant of the brain. There is 
evidence of oxidative stress, lowered brain glutathione and genetic link-
age involve glutathione metabolic genes in schizophrenia and bipolar 
disorder. N-acetyl cysteine (NAC) is a safe, orally bioavailable, precursor 
of glutathione. NAC has been shown to reverse animal models of oxida-
tive stress, and raises brain glutathione levels. objectives: To test the 
efficacy of NAC as an adjunct treatment for schizophrenia and for bipolar 
disorder. Methods: We performed double-blind, multicenter, randomised 
placebo-controlled trials, 140 people with schizophrenia and a separate 
RCT with 75 individuals with bipolar disorder. In both trials subjects re-
ceived 2g daily of NAC or placebo as add-on therapy to treatment as 
usual. Outcomes in the schizophrenia trial included the Clinical Global 
Impression (CGI) Severity and Improvement scales, the Positive and Nega-
tive Symptoms Scale (PANSS) and measures of general functioning and 
extrapyramidal side effects. Outcome measures in the bipolar study in-
cluded measures of mania, depression, CGI, substance use, quality of life, 
functioning, and tolerability. The duration of both trials was 6 months. 
results: Intent-to-treat analysis of the schizophrenia trial revealed that 
NAC significantly improved PANSS total (p= .009], PANSS negative, (p= 
.018], and PANSS general (p= .035], CGI-Severity (p= .004], and CGI-
Improvement (p= .025) scores. NAC treatment in the bipolar trial caused 
a significant improvement on the MADRS (p = .002) and most secondary 
scales at end point. Conclusions: These trials implicate glutathione deficits 
in the pathophysiology of these disorders, and supports NAC as a novel 
adjunctive treatment for both conditions. References: Berk et al. N-Acetyl 
Cysteine as a Glutathione Precursor for Schizophrenia: A Double-Blind, 
Randomized, Placebo-Controlled Trial. Biological Psychiatry 2008; 64, 
361; Berk et al. N-Acetyl Cysteine for Depressive Symptoms in Bipolar 
Disorder: A Double-Blind, Randomized, Placebo-Controlled Trial. Biologi-
cal Psychiatry 2008; 64, 468.
Fc-32-003
prevalence of lower-than-expected plasma levels in medicated pa-
tients presenting for acute inpatient treatment
Christian Geretsegger
Paracelsus Med. Universität, Psychiatrie und Psychother., Salzburg, 
Austria
Wolfgang Aichhorn, Christoph Stuppaeck, Renate Stelzig, Christoph 
Egger, Marina Hornsteiner, Karl Voglreiter, Alois Saria, Georg Kemmler, 
Gerald Zernig
objectives: Non-compliance or incomplete compliance with psychophar-
macological medication by psychiatric patients is a frequent risk, preva-
lence rates ranging from 18 to 70% (numerical mean 44%). 
methods: All patients who had to be admitted to the psychiatric inpa-
tient wards of the University Clinics of Psychiatry and Psychotherapy I, Pa-
racelsus Medical University, Christian Doppler Clinics from 01 June 2005 
to 15 July 2005 were screened for pre-admission psychiatric medication. 
Plasma levels of antidepressants and antipsychotics were determined af-
ter solid-phase extraction by high performance liquid chromatography/
mass spectrometry (LC/MS). 
results: A total of 233 acute psychiatric admissions occurred, in the case 
of 58 admissions, patients did not have any pre-medication. The type of 
medication could not be determined in one patient, and the dose in 4 
patients, nine patients had a pre-medication other than antidepressants 
or antipsychotics, remaining 161 admissions for the statistical analysis. 
52% (83 of 161) of the admissions had actual plasma levels that were 
>2-fold below the plasma level that could be expected from their pre-
scribed dosage, 21% (34 of 161) had actual plasma levels that were >2-
fold above, including 23 (14.3%) patients had a plasma level of 0.0 ng/
ml at admission 
conclusions: Our findings show, that under routine conditions, 52% of 
medicated patients had actual plasma levels that were more than 2-fold 
lower than the plasma levels that could be expected from the prescribed 
dosage. Our findings suggest that the risk for a patient of NOT having the 
intended level of medication in his/her blood is 3:1. 
Fc-32-004
the anxiolytic etifoxine reduces the physical signs and anxiogenic 
effects of ethanol withdrawal in mice
Marc Verleye
Biocodex, Dept. of Pharmacology, Compiègne, France
Isabelle Heulard, Jean-Marie Gillardin
objectives: Change in the function of gamma-aminobutyric acidA 
(GABAA) receptors attributable to alterations in receptor subunit com-
position, is one of main molecular mechanisms with those affecting the 
glutamatergic system which accompany prolonged ethanol intake. These 
changes explain in part the central nervous system hyperexcitability con-
sequently to ethanol administration cessation. In animal models as well 
as in humans, hyperexcitability associated with ethanol withdrawal ex-
presses by physical signs such as convulsions and heightened anxiety. The 
present work investigated the effects of anxiolytic compound etifoxine on 
ethanol withdrawal paradigms in a mouse model. The benzodiazepine 
diazepam was chosen as reference compound.
methods: Ethanol was given to NMRI mice by a liquid diet at 3% for 8 
days then at 4% for 7 days. Under these conditions, ethanol blood level 
ranged between 0.5 to 2g/l for a daily ethanol intake varying from 24 
to 30g/kg. The convulsive behaviour on handling was scored on a rating 
scale (Watson et al., 1997) whereas anxiety-like behaviour was measured 
in the light/dark box test. Possible sedative and ataxic effects of etifoxine 
using the actimeter and rota rod tests were evaluated in normal animals.
results: Etifoxine (12.5-25mg/kg) and diazepam (1-4mg/kg) injected 
intraperitoneally 3h30min after ethanol removal, decreased the sever-
ity in handling-induced tremors and convulsions in the period of 4 to 
6h after ethanol withdrawal. In addition, when administered 30min and 
15min respectively before the light/dark box test, etifoxine (50 mg/kg) 
and diazepam (1mg/kg) inhibited enhanced aversive response 8 h after 
ethanol withdrawal. Contrary to diazepam, etifoxine had no effects on 
spontaneous locomotor activity and did not exhibit ataxic effects in nor-
mal animals.
